These results have important implications for the food industry
The pharmaceutical industry is developing newer and potentially cheaper or more effective molecules that target GLP-1 and associated pathways (for example, the so-called dual- and triple-agonists tirzepatide, retatutride and orfoglipon) 257,258
L-arginine can stimulate GLP-1 production
[1] [5] Currently available GLP-1 medications in the United States include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GLP-1/GIP receptor agonist
Ideal candidates for injections typically exhibit the following characteristics: Unsuccessful Weight Loss Programs Patients who have made previous efforts to lose weight through lifestyle modifications such as diet and exercise but have been unsuccessful in achieving sustainable results
At the 12-week mark, we look for one specific number: has the patient lost at least 5% of their starting body weight
